Consistent response
Achieve a consistent platelet response
with Doptelet1
In the Phase 3 trial, the median platelet count was consistently higher with Doptelet vs placebo from day 8 (80.5 x 109/L vs 8 x 109/L).1
Median platelet count over time1
Figure is drawn up by Sobi as a rendering of figure 3A p 486 in ref 1.
Doptelet is indicated for the treatment of severe thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo aninvasive procedure. 2
Doptelet is indicated for the treatment of primary chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins). 2
ITP, immune thrombocytopenia; TPO-RA, thrombopoietin receptor agonist.
References
1. Jurczak W, Chojnowski K, Mayer J, et al. Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia. Br J Haematol. 2018;183(3):479-490. 2. Doptelet Summary of Product Characteristics. 22/05/2025.